These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35035729)

  • 21. Effect of combined bevacizumab and temozolomide treatment on intramedullary spinal cord tumor.
    Gwak SJ; An SS; Yang MS; Joe E; Kim DH; Yoon DH; Kim KN; Ha Y
    Spine (Phila Pa 1976); 2014 Jan; 39(2):E65-73. PubMed ID: 24158177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
    Parlato C; Barbarisi M; Moraci M; Moraci A
    Front Biosci; 2006 May; 11():1280-3. PubMed ID: 16368514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temozolomide chemotherapy combined with radiotherapy versus radiotherapy alone after surgery in patients with high-risk low-grade gliomas.
    Hou Y; Huan Y; Zhang Y; Liu X; Li Y
    J BUON; 2021; 26(3):977-983. PubMed ID: 34268962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fractionated stereotactic radiotherapy plus bevacizumab after response to bevacizumab plus irinotecan as a rescue treatment for high-grade gliomas.
    Conde-Moreno AJ; García-Gómez R; Albert-Antequera M; Almendros-Blanco P; De Las Peñas-Bataller R; González-Vidal V; López-Torrecilla JL; Ferrer-Albiach C
    Rep Pract Oncol Radiother; 2015; 20(3):231-8. PubMed ID: 25949228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
    Herrlinger U; Schäfer N; Steinbach JP; Weyerbrock A; Hau P; Goldbrunner R; Friedrich F; Rohde V; Ringel F; Schlegel U; Sabel M; Ronellenfitsch MW; Uhl M; Maciaczyk J; Grau S; Schnell O; Hänel M; Krex D; Vajkoczy P; Gerlach R; Kortmann RD; Mehdorn M; Tüttenberg J; Mayer-Steinacker R; Fietkau R; Brehmer S; Mack F; Stuplich M; Kebir S; Kohnen R; Dunkl E; Leutgeb B; Proescholdt M; Pietsch T; Urbach H; Belka C; Stummer W; Glas M
    J Clin Oncol; 2016 May; 34(14):1611-9. PubMed ID: 26976423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.
    Nagane M; Kobayashi K; Tanaka M; Tsuchiya K; Shishido-Hara Y; Shimizu S; Shiokawa Y
    Int J Clin Oncol; 2014 Feb; 19(1):16-23. PubMed ID: 23354833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis.
    Yonezawa H; Hirano H; Uchida H; Habu M; Hanaya R; Oyoshi T; Sadamura Y; Hanada T; Tokimura H; Moinuddin F; Arita K
    Mol Clin Oncol; 2017 Jan; 6(1):105-110. PubMed ID: 28123740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of synchronous stereotactic radiotherapy with temozolomide combined with whole brain radiotherapy in treating brain metastases originating from non-small cell lung cancer.
    Liu P; Ren R; You D; Liu J
    J BUON; 2020; 25(4):1771-1778. PubMed ID: 33099912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene expression profiling predicts response to temozolomide in malignant gliomas.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
    Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and mechanism of osimertinib combined with bevacizumab in the treatment of postoperative EGFR positive stage II-IIIA lung adenocarcinoma.
    Bao J; Wu Z; Zhang C; Zhang M; Wang Y; Li H; Sun X; Gao J; Ge L; Li Y; Wang H; Guo Q
    Am J Transl Res; 2022; 14(1):633-642. PubMed ID: 35173881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E
    Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
    Gil MJ; de Las Peñas R; Reynés G; Balañá C; Peréz-Segura P; García-Velasco A; Mesia C; Gallego O; Fernández-Chacón C; Martínez-García M; Herrero A; Andrés R; Benavides M; Quintanar T; Pérez-Martin X
    Anticancer Drugs; 2012 Jul; 23(6):659-65. PubMed ID: 22634799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Favorable outcome in the elderly cohort treated by concomitant temozolomide radiochemotherapy in a multicentric phase II safety study of 5-ALA.
    Stummer W; Nestler U; Stockhammer F; Krex D; Kern BC; Mehdorn HM; Vince GH; Pichlmeier U
    J Neurooncol; 2011 Jun; 103(2):361-70. PubMed ID: 20922459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
    Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
    Towner RA; Ihnat M; Saunders D; Bastian A; Smith N; Pavana RK; Gangjee A
    BMC Cancer; 2015 Jul; 15():522. PubMed ID: 26177924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etoposide plus cisplatin chemotherapy improves the efficacy and safety of small cell lung cancer.
    Wang Z; Mai S; Lv P; Xu L; Wang Y
    Am J Transl Res; 2021; 13(11):12825-12833. PubMed ID: 34956497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis.
    Jiang G; Li RH; Sun C; Jia HY; Lei TC; Liu YQ
    Tumour Biol; 2014 Jan; 35(1):315-22. PubMed ID: 24163082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.
    Grossman R; Rudek MA; Brastianos H; Zadnik P; Brem H; Tyler B; Blakeley JO
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):129-39. PubMed ID: 22644796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).
    Reyes-Botero G; Cartalat-Carel S; Chinot OL; Barrie M; Taillandier L; Beauchesne P; Catry-Thomas I; Barrière J; Guillamo JS; Fabbro M; Frappaz D; Benouaich-Amiel A; Le Rhun E; Campello C; Tennevet I; Ghiringhelli F; Tanguy ML; Mokhtari K; Honnorat J; Delattre JY
    Oncologist; 2018 May; 23(5):524-e44. PubMed ID: 29472310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.